Intellia Therapeutics, Inc. (NASDAQ:NTLA) reported Q2 2017 earnings this Morning, coming in at ($0.45) per share, missing Wall Street’s estimates of ($0.42) per Share. Revenue for the quarter came in at $5.90 million beating analyst estimates of $5.83 million
Analyst Coverage For Intellia Therapeutics, Inc. (NASDAQ:NTLA)
These are 2 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Intellia Therapeutics, Inc. (NASDAQ:NTLA) is Buy (Score: 2.75) with a consensus target price of $27.50 , a potential (63.30% upside)Recent Insider Trading for Intellia Therapeutics, Inc. (NASDAQ:NTLA)
- On 7/11/2017 Venture Fund Ix L.P. Atlas, Major Shareholder, sold 150,000 with an average share price of $16.24 per share and the total transaction amounting to $2,436,000.00.
- On 3/10/2017 Jean Francois Formela, Director, sold 21,132 with an average share price of $13.91 per share and the total transaction amounting to $293,946.12.
- On 5/11/2016 Bros. Advisors Lp Baker, Insider, bought 200,000 with an average share price of $18.00 per share and the total transaction amounting to $3,600,000.00.
- On 5/11/2016 Carl L Gordon, Director, bought 250,000 with an average share price of $18.00 per share and the total transaction amounting to $4,500,000.00.
- On 5/11/2016 Institutes For Biomed Novartis, Major Shareholder, bought 277,777 with an average share price of $18.00 per share and the total transaction amounting to $4,999,986.00.
Recent Trading for Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares of Intellia Therapeutics, Inc. closed the previous trading session at 15.87 down -0.97 -5.76% with 160,192 shares trading hands.